Sotera Health Company $SHC is Sculptor Capital LP's 8th Largest Position

Key Points

• Sculptor Capital LP increased its stake in Sotera Health Company by 80.8% in Q1, making it the firm’s 8th largest position with 9,037,511 shares valued at approximately $105.4 million.
• Several analysts have upgraded Sotera Health's stock ratings, with Goldman Sachs raising it to a buy rating and increasing the price target from $14.00 to $17.00.
• Sotera Health recently reported an earnings per share (EPS) of $0.20 for the quarter, exceeding expectations, and has set its FY 2025 EPS guidance between 0.750-0.820.

Sculptor Capital LP raised its position in Sotera Health Company (NASDAQ:SHC - Free Report) by 80.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,037,511 shares of the company's stock after purchasing an additional 4,037,511 shares during the period. Sotera Health accounts for 2.0% of Sculptor Capital LP's investment portfolio, making the stock its 8th largest holding. Sculptor Capital LP owned approximately 3.18% of Sotera Health worth $105,377,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Farther Finance Advisors LLC increased its position in shares of Sotera Health by 4,881.9% in the 1st quarter. Farther Finance Advisors LLC now owns 6,327 shares of the company's stock valued at $70,000 after purchasing an additional 6,200 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Sotera Health in the 1st quarter valued at approximately $266,000. BNP Paribas Financial Markets purchased a new stake in shares of Sotera Health in the 4th quarter valued at approximately $208,000. Principal Financial Group Inc. increased its position in shares of Sotera Health by 0.3% in the 1st quarter. Principal Financial Group Inc. now owns 352,388 shares of the company's stock valued at $4,109,000 after purchasing an additional 1,037 shares during the last quarter. Finally, Ananym Capital Management LP purchased a new stake in shares of Sotera Health in the 4th quarter valued at approximately $13,680,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SHC has been the subject of several research analyst reports. The Goldman Sachs Group upgraded shares of Sotera Health from a "neutral" rating to a "buy" rating and upped their target price for the company from $14.00 to $17.00 in a report on Monday, May 5th. Barclays restated an "overweight" rating on shares of Sotera Health in a report on Friday, August 8th. Finally, Wall Street Zen upgraded shares of Sotera Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Sotera Health presently has an average rating of "Moderate Buy" and a consensus price target of $16.00.

Sotera Health Stock Performance

NASDAQ:SHC traded up $0.17 during trading hours on Monday, reaching $16.37. 1,031,549 shares of the company's stock were exchanged, compared to its average volume of 1,770,046. The firm has a market capitalization of $4.65 billion, a price-to-earnings ratio of 204.65 and a beta of 1.83. The company has a 50-day moving average of $12.98 and a 200 day moving average of $12.27. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 4.49. Sotera Health Company has a 1-year low of $9.53 and a 1-year high of $17.08.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.03. The firm had revenue of $294.34 million during the quarter, compared to analysts' expectations of $275.81 million. Sotera Health had a net margin of 2.14% and a return on equity of 39.42%. Sotera Health's quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.19 EPS. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. Research analysts anticipate that Sotera Health Company will post 0.61 EPS for the current year.

Insiders Place Their Bets

In related news, insider Michael P. Rutz sold 126,611 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $16.38, for a total transaction of $2,073,888.18. Following the completion of the sale, the insider owned 450,204 shares in the company, valued at $7,374,341.52. This represents a 21.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 55.12% of the stock is currently owned by corporate insiders.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.